Inactive Instrument

Celltrion, Inc. Stock Korea S.E.

Equities

068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
- KRW - Intraday chart for Celltrion, Inc.
Sales 2024 * 3,428B 2.49B Sales 2025 * 4,172B 3.03B Capitalization 37,040B 26.89B
Net income 2024 * 505B 367M Net income 2025 * 1,099B 798M EV / Sales 2024 * 11 x
Net Debt 2024 * 656B 476M Net Debt 2025 * 297B 215M EV / Sales 2025 * 8.95 x
P/E ratio 2024 *
71.6 x
P/E ratio 2025 *
33.3 x
Employees -
Yield 2024 *
0.23%
Yield 2025 *
0.24%
Free-Float 63.67%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 62 07-04-23
Director of Finance/CFO 49 -
Chairman 66 -
Members of the board TitleAgeSince
Director/Board Member 73 -
Chairman 66 -
Director/Board Member 72 14-12-07
More insiders
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
More about the company